ClinicalTrials.gg
CompletedNCT01455415Updated Jan 28, 2021Results posted

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

A Phase 3 interventional study of pregabalin and placebo in Painful Diabetic Peripheral Neuropathy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 61 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is to test the effectiveness of pregabalin in treating nerve pain caused by diabetes. The suitable subjects will be patients who also use an non-steroid anti-inflammatory drug for another pain which is not related to the diabetic nerve pain.

02

Conditions studied

  • Painful Diabetic Peripheral Neuropathy
03

In context

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 or 2 diabetes with painful neuropathy
  • Currently treated with one NSAID (including COX 2 inhibitors) for a co morbid pain condition with a regular dose
  • Meet pre-defined level of pain severity at entrance

Exclusion criteria

Exclusion Criteria:

  • History of failed pregabalin treatment due to lack of efficacy at therapeutic dose
  • Participated in a previous or ongoing pregabalin clinical trial
  • Neurologic disorders unrelated to diabetic neuropathy that may confound the assessment of distal neuropathic pain
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    1: Pregabalin

    Drug: pregabalin

  • Placebo comparator
    2: Placebo

    Drug: placebo

Interventions

  • 150 - 300 mg/day in divided dose (3 time a day) for 6 weeks

  • Drugplacebo

    matching placebo 3 time a day

06

What researchers measure

Primary outcomes

  1. Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)

    The daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self assessment was performed daily in the evening before bedtime on a telephone via interactive voice recognition system (IVRS) (time window for completion between 6.00 pm to midnight). The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study drug in each treatment period - period 1 and period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

    Time frame: End of Period (includes both Visits 5 and 9)

Secondary outcomes

  1. Percentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    Daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self assessment was performed daily in the evening before bedtime on a telephone via IVRS (time window for completion between 6.00 pm to midnight). The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study drug in each treatment period - period 1 and period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

    Time frame: End of Period (includes both Visits 5 and 9)

  2. Percentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    Daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self assessment was performed daily in the evening before bedtime on a telephone via IVRS (time window for completion between 6.00 pm to midnight). The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study drug in each treatment period - period 1 and period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

    Time frame: End of Period (includes both Visits 5 and 9)

  3. Brief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. Four items measure pain (0: no pain; 10: worst pain possible) at its "worst, "least", "average", and "now" (current pain) on an 11-point scale. Scores range from 0 - 10 with higher scores indicating greater pain severity.

    Time frame: End of Period (includes both Visits 5 and 9)

  4. BPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. Seven sub-questions evaluates the level of interference of pain on daily functioning (general activity, walking, work ability, mood, enjoyment of life, relations with other people, and sleep) on an 11-point scale (0: does not interfere; 10: completely interferes). Scores range from 0 - 10 with higher scores indicating greater interference.

    Time frame: End of Period (includes both Visits 5 and 9)

  5. Mean Sleep Interference Rating Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The daily sleep diary consists of an 11-point numeric rating scale with which the participant rates how painful DPN pain has interfered with their sleep during the past 24 hours. Zero indicates "does not interfere with sleep" and 10 indicates "completely interferes (unable to sleep due to pain)". Self assessment was performed daily in the evening before bedtime on a telephone via IVRS (time window for completion between 6.00 pm to midnight) after completion of the daily pain diary.

    Time frame: End of Period (includes both Visits 5 and 9)

  6. Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The Hospital Anxiety and Depression Scale (HADS) is a 14- item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4- point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.

    Time frame: End of Period (includes both Visits 5 and 9)

  7. HADS-D Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    HADS is a 14- item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4- point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.

    Time frame: End of Period (includes both Visits 5 and 9)

  8. Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL) Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. TQOL score should be summed as follow: sum (Σ) (1 - 7, 8 - 35). The (sub)scales are calculated without weighting of any kind, and reported as the integer sum of listed questionnaire items (range: -4 - 136). The QOL-DN version that was administered in this study was modified with a 2-week recall period.

    Time frame: End of Period (includes both Visits 5 and 9)

  9. Norfolk QOL-DN Symptoms Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess the impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. Item 9 is scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). The symptoms domain score should be summed as follow: Σ (1 - 7, 9). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items (range: 0 - 32). The QOL-DN version that was administered in this study was modified with a 2-week recall period.

    Time frame: End of Period (includes both Visits 5 and 9)

  10. Norfolk QOL-DN Activities of Daily Living Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess the impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. The items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). Activities of the daily living domain score should be summed as follow: Σ (12, 22, 23, 25, 26). Scales and subscales are calculated without weighting of any kind, and reported as integer sum of listed questionnaire items (range: 0 - 20). The QOL-DN version that was administered in the study was modified with a 2-week recall period.

    Time frame: End of Period (includes both Visits 5 and 9)

  11. Norfolk QOL-DN Physical Functioning / Large Fiber Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess the impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. With exception of questions 31 and 32, items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", middle item, is scored as 0, "very good" as -1 , "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. Physical functioning / large fiber domain score should be summed as follow: Σ (8, 11, 13 - 15, 24, 27 - 35). Scales and subscales are calculated without weighting of any kind, and reported as integer sum of listed questionnaire items (range: -4 - 56). QOL-DN version that was administered in the study was modified with a 2-week recall period.

    Time frame: End of Period (includes both Visits 5 and 9)

  12. Norfolk QOL-DN Small Fiber Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. The items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). The small fiber domain score should be summed as follow: Σ (10, 16, 17, 18). Scales and subscales are calculated without weighting of any kind, and reported as integer sum of the listed questionnaire items (range: 0 - 16). The QOL-DN version that was administered in this study was modified with a 2-week recall period.

    Time frame: End of Period (includes both Visits 5 and 9)

  13. Norfolk QOL-DN Autonomic Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess the impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. The items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). The autonomic domain score should be summed as follow: Σ (19, 20, 21). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items (range: 0 - 12). The QOL-DN version that was administered in this study was modified with a 2-week recall period.

    Time frame: End of Period (includes both Visits 5 and 9)

  14. Euro QoL-5 Dimensions (EQ-5D) Mobility Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale (no problems, some/moderate problems, extreme problems) and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

    Time frame: End of Period (includes both Visits 5 and 9)

  15. EQ-5D Self-Care Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

    Time frame: End of Period (includes both Visits 5 and 9)

  16. EQ-5D Usual Activities Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

    Time frame: End of Period (includes both Visits 5 and 9)

  17. EQ-5D Pain / Discomfort Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

    Time frame: End of Period (includes both Visits 5 and 9)

  18. EQ-5D Anxiety / Depression Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

    Time frame: End of Period (includes both Visits 5 and 9)

  19. EQ-5D Dolan 1997 Index Summary Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health. The utility score is calculated using the Dolan 1997 algorithm and the revised version which was provided to the EuroQol Group by Dolan in 2001 - but later published in medical care in 2002.

    Time frame: End of Period (includes both Visits 5 and 9)

  20. EQ-5D Dolan 2002 Index Summary Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health. The utility score is calculated using the Dolan 1997 algorithm and the revised version which was provided to the EuroQol Group by Dolan in 2001 - but later published in medical care in 2002.

    Time frame: End of Period (includes both Visits 5 and 9)

  21. Patient Global Impression of Change (PGIC) Score at the End of Period 1 (Week 6) - Original Scores

    The PGIC is a participant-rated instrument that measures the participant's assessment of change in his/her overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). Due to the crossover design, PGIC was analyzed at the end of period 1 (V5).

    Time frame: End of Period 1 (V5)

  22. PGIC Score at the End of Period 1 (Week 6) - Categorized Scores

    The PGIC is a participant-rated instrument that measures the participant's assessment of change in his/her overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). Original scores (7 different scores) and categorized scores (4 different scores) were provided. Categorized scores were very much improved (consisting of very much improved and much improved); any improvement (consisting of very much improved, much improved, and minimally improved); no change (consisting of no change); and any worsening (consisting of minimally worse, much worse, and very much worse). Due to the crossover design, PGIC was analyzed at the end of period 1 (V5).

    Time frame: End of Period 1 (V5)

07

Results

Posted Apr 23, 2015

Participant flow

501 participants were screened, of whom 197 were withdrawn before randomization. 304 were randomized, of whom 3 discontinued before being treated. Participants were randomized at 47 centers in 3 countries: US (43), Czech Republic (3), and Italy (1). 4 centers received study drug but did not randomize participants.

Period 1
Participant flow — Period 1
MilestonePregabalin/PlaceboPlacebo/Pregablin
Started154147
Completed135123
Not completed1924
Withdrew: Adverse event (ae) related to study drug96
Withdrew: Lost to follow-up related to study drug33
Withdrew: Drug error not associated to ae01
Withdrew: Ae not related to study drug26
Withdrew: Withdrawal by subject45
Withdrew: Unspecified reason11
Withdrew: Protocol violation02
Washout
Participant flow — Washout
MilestonePregabalin/PlaceboPlacebo/Pregablin
Started135123
Completed127116
Not completed87
Withdrew: Ae related to study drug20
Withdrew: Lost to follow-up10
Withdrew: Drug error not associated to ae21
Withdrew: Ae not related to study drug23
Withdrew: Unspecified reason12
Withdrew: Protocol violation01
Period 2
Participant flow — Period 2
MilestonePregabalin/PlaceboPlacebo/Pregablin
Started127116
Completed114106
Not completed1310
Withdrew: Ae related to study drug12
Withdrew: Lost to follow-up21
Withdrew: Ae not related to study drug21
Withdrew: Lack of efficacy20
Withdrew: Withdrawal by subject23
Withdrew: Unspecified reason23
Withdrew: Protocol violation20
Follow-up
Participant flow — Follow-up
MilestonePregabalin/PlaceboPlacebo/Pregablin
Started114106
Completed111104
Not completed32
Withdrew: Ae related to study drug01
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject20
Withdrew: Unspecified reason10

Outcome measures

SecondaryPercentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)

Daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self assessment was performed daily in the evening before bedtime on a telephone via IVRS (time window for completion between 6.00 pm to midnight). The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study drug in each treatment period - period 1 and period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)
percentage of participantsPregabalinPlacebo
Percentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)34.5631.16
Statistical analysis
  • Pregabalin vs Placebo · Regression, Logistic · p = 0.3287 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Odds ratio (or): 1.20 · 95% CI 0.83 to 1.73
SecondaryPercentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)

Daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self assessment was performed daily in the evening before bedtime on a telephone via IVRS (time window for completion between 6.00 pm to midnight). The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study drug in each treatment period - period 1 and period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)
percentage of participantsPregabalinPlacebo
Percentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)20.2215.58
Statistical analysis
  • Pregabalin vs Placebo · Regression, Logistic · p = 0.0625 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Odds ratio (or): 1.57 · 95% CI 0.98 to 2.51
SecondaryBrief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. Four items measure pain (0: no pain; 10: worst pain possible) at its "worst, "least", "average", and "now" (current pain) on an 11-point scale. Scores range from 0 - 10 with higher scores indicating greater pain severity.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Brief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Brief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)4.49 ± 0.114.48 ± 0.11
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.9448 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): 0.01 · 95% CI -0.21 to 0.22
SecondaryBPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. Seven sub-questions evaluates the level of interference of pain on daily functioning (general activity, walking, work ability, mood, enjoyment of life, relations with other people, and sleep) on an 11-point scale (0: does not interfere; 10: completely interferes). Scores range from 0 - 10 with higher scores indicating greater interference.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
BPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
BPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)3.50 ± 0.123.59 ± 0.11
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.4548 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.09 · 95% CI -0.32 to 0.14
SecondaryMean Sleep Interference Rating Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The daily sleep diary consists of an 11-point numeric rating scale with which the participant rates how painful DPN pain has interfered with their sleep during the past 24 hours. Zero indicates "does not interfere with sleep" and 10 indicates "completely interferes (unable to sleep due to pain)". Self assessment was performed daily in the evening before bedtime on a telephone via IVRS (time window for completion between 6.00 pm to midnight) after completion of the daily pain diary.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Mean Sleep Interference Rating Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Mean Sleep Interference Rating Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)4.11 ± 0.124.35 ± 0.12
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0272 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.24 · 95% CI -0.44 to -0.03
SecondaryHospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The Hospital Anxiety and Depression Scale (HADS) is a 14- item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4- point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)4.90 ± 0.184.96 ± 0.18
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.7344 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.06 · 95% CI -0.42 to 0.30
SecondaryHADS-D Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

HADS is a 14- item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4- point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
HADS-D Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
HADS-D Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)4.42 ± 0.174.50 ± 0.17
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.6007 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.09 · 95% CI -0.42 to 0.24
SecondaryNorfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL) Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. TQOL score should be summed as follow: sum (Σ) (1 - 7, 8 - 35). The (sub)scales are calculated without weighting of any kind, and reported as the integer sum of listed questionnaire items (range: -4 - 136). The QOL-DN version that was administered in this study was modified with a 2-week recall period.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL) Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL) Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)37.22 ± 1.0338.30 ± 1.02
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.2987 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -1.08 · 95% CI -3.13 to 0.96
SecondaryNorfolk QOL-DN Symptoms Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess the impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. Item 9 is scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). The symptoms domain score should be summed as follow: Σ (1 - 7, 9). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items (range: 0 - 32). The QOL-DN version that was administered in this study was modified with a 2-week recall period.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Symptoms Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Symptoms Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)7.51 ± 0.257.86 ± 0.25
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.1769 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.35 · 95% CI -0.85 to 0.16
SecondaryNorfolk QOL-DN Activities of Daily Living Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess the impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. The items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). Activities of the daily living domain score should be summed as follow: Σ (12, 22, 23, 25, 26). Scales and subscales are calculated without weighting of any kind, and reported as integer sum of listed questionnaire items (range: 0 - 20). The QOL-DN version that was administered in the study was modified with a 2-week recall period.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Activities of Daily Living Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Activities of Daily Living Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)2.82 ± 0.162.94 ± 0.16
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.5119 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.12 · 95% CI -0.48 to 0.24
SecondaryNorfolk QOL-DN Physical Functioning / Large Fiber Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess the impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. With exception of questions 31 and 32, items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", middle item, is scored as 0, "very good" as -1 , "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. Physical functioning / large fiber domain score should be summed as follow: Σ (8, 11, 13 - 15, 24, 27 - 35). Scales and subscales are calculated without weighting of any kind, and reported as integer sum of listed questionnaire items (range: -4 - 56). QOL-DN version that was administered in the study was modified with a 2-week recall period.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Physical Functioning / Large Fiber Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Physical Functioning / Large Fiber Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)23.17 ± 0.6123.66 ± 0.60
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.4335 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.49 · 95% CI -1.72 to 0.74
SecondaryNorfolk QOL-DN Small Fiber Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. The items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). The small fiber domain score should be summed as follow: Σ (10, 16, 17, 18). Scales and subscales are calculated without weighting of any kind, and reported as integer sum of the listed questionnaire items (range: 0 - 16). The QOL-DN version that was administered in this study was modified with a 2-week recall period.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Small Fiber Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Small Fiber Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)2.57 ± 0.162.58 ± 0.16
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.9653 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.01 · 95% CI -0.31 to 0.30
SecondaryNorfolk QOL-DN Autonomic Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess the impact of diabetic neuropathy on quality of life of participants with diabetic neuropathy. The items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). The autonomic domain score should be summed as follow: Σ (19, 20, 21). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items (range: 0 - 12). The QOL-DN version that was administered in this study was modified with a 2-week recall period.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Autonomic Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Autonomic Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)1.12 ± 0.101.26 ± 0.10
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.2690 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.14 · 95% CI -0.38 to 0.11
SecondaryEuro QoL-5 Dimensions (EQ-5D) Mobility Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale (no problems, some/moderate problems, extreme problems) and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Euro QoL-5 Dimensions (EQ-5D) Mobility Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Euro QoL-5 Dimensions (EQ-5D) Mobility Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)1.65 ± 0.031.65 ± 0.03
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.9951 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): 0.00 · 95% CI -0.05 to 0.05
SecondaryEQ-5D Self-Care Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
EQ-5D Self-Care Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
EQ-5D Self-Care Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)1.18 ± 0.021.18 ± 0.02
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.9726 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): 0.00 · 95% CI -0.05 to 0.05
SecondaryEQ-5D Usual Activities Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
EQ-5D Usual Activities Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
EQ-5D Usual Activities Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)1.53 ± 0.031.51 ± 0.03
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.5497 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): 0.02 · 95% CI -0.04 to 0.08
SecondaryEQ-5D Pain / Discomfort Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
EQ-5D Pain / Discomfort Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
EQ-5D Pain / Discomfort Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)2.03 ± 0.031.98 ± 0.02
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.1495 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): 0.05 · 95% CI -0.02 to 0.11
SecondaryEQ-5D Anxiety / Depression Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
EQ-5D Anxiety / Depression Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
EQ-5D Anxiety / Depression Domain Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)1.30 ± 0.031.35 ± 0.03
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.1297 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.05 · 95% CI -0.11 to 0.01
SecondaryEQ-5D Dolan 1997 Index Summary Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health. The utility score is calculated using the Dolan 1997 algorithm and the revised version which was provided to the EuroQol Group by Dolan in 2001 - but later published in medical care in 2002.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
EQ-5D Dolan 1997 Index Summary Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
EQ-5D Dolan 1997 Index Summary Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)0.63 ± 0.010.65 ± 0.01
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.4279 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.01 · 95% CI -0.04 to 0.02
SecondaryEQ-5D Dolan 2002 Index Summary Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

EQ-5D is a participant-completed 5-item questionnaire designed to assess health related quality of life in terms of a single index value or utility score. There are 5 dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale \[1 = no problems, 2 = some/moderate problems, 3 = extreme problems\] and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health. The utility score is calculated using the Dolan 1997 algorithm and the revised version which was provided to the EuroQol Group by Dolan in 2001 - but later published in medical care in 2002.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
EQ-5D Dolan 2002 Index Summary Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
EQ-5D Dolan 2002 Index Summary Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)0.63 ± 0.010.64 ± 0.01
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.5505 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.) · Mean difference (final values): -0.01 · 95% CI -0.04 to 0.02
SecondaryPatient Global Impression of Change (PGIC) Score at the End of Period 1 (Week 6) - Original Scores

The PGIC is a participant-rated instrument that measures the participant's assessment of change in his/her overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). Due to the crossover design, PGIC was analyzed at the end of period 1 (V5).

Time frame:
End of Period 1 (V5)
Reported as:
Number · percentage of participants
Patient Global Impression of Change (PGIC) Score at the End of Period 1 (Week 6) - Original Scores
percentage of participantsPregabalinPlacebo
Very much improved8.14.9
Much improved27.719.6
Minimally improved39.239.2
No change14.923.1
Minimally worse6.17.0
Much worse2.01.4
Very much worse1.42.1
Missing0.72.8
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.0604 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.)
PrimaryAverage Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)

The daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self assessment was performed daily in the evening before bedtime on a telephone via interactive voice recognition system (IVRS) (time window for completion between 6.00 pm to midnight). The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study drug in each treatment period - period 1 and period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

Time frame:
End of Period (includes both Visits 5 and 9)
Reported as:
Least squares mean · units on a scale
Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)4.980 ± 0.1275.018 ± 0.126
Statistical analysis
  • Pregabalin vs Placebo · Repeated measure mixed effects model · p = 0.7174 (Primary analysis was two-sided and performed at the 0.05 significance level.) · Mean difference (final values): -0.038 · 95% CI -0.248 to 0.171The Kenward-Roger method was used to estimate denominator degrees of freedom.
SecondaryPGIC Score at the End of Period 1 (Week 6) - Categorized Scores

The PGIC is a participant-rated instrument that measures the participant's assessment of change in his/her overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). Original scores (7 different scores) and categorized scores (4 different scores) were provided. Categorized scores were very much improved (consisting of very much improved and much improved); any improvement (consisting of very much improved, much improved, and minimally improved); no change (consisting of no change); and any worsening (consisting of minimally worse, much worse, and very much worse). Due to the crossover design, PGIC was analyzed at the end of period 1 (V5).

Time frame:
End of Period 1 (V5)
Reported as:
Number · percentage of participants
PGIC Score at the End of Period 1 (Week 6) - Categorized Scores
percentage of participantsPregabalinPlacebo
Very much/much improved35.824.5
Any improvement75.063.6
No change14.923.1
Any worsening9.510.5
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.1511 (Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.)

Adverse events

Collected over From the time the participants were randomized through and including 28 calender days after the last administration of the study drug.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—5/272 (1.8%)84/272 (30.9%)
Placebo—7/276 (2.5%)45/276 (16.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPregabalinPlacebo
Angina pectorisCardiac disorders1/2720/276
Atrial fibrillationCardiac disorders1/2720/276
Myocardial infarctionCardiac disorders1/2720/276
Multi-organ failureGeneral disorders1/2720/276
BronchitisInfections and infestations1/2720/276
Escherichia bacteraemiaInfections and infestations1/2720/276
HyperglycaemiaMetabolism and nutrition disorders1/2720/276
Abdominal pain upperGastrointestinal disorders0/2721/276
GastritisGastrointestinal disorders0/2721/276
Pancreatitis acuteGastrointestinal disorders0/2721/276
Most frequent other events
Most frequent other events
EventPregabalinPlacebo
DizzinessNervous system disorders28/2724/276
FatigueGeneral disorders14/2724/276
SomnolenceNervous system disorders14/2727/276
DiarrhoeaGastrointestinal disorders9/27211/276
Oedema peripheralGeneral disorders10/2728/276
NauseaGastrointestinal disorders9/2728/276
HeadacheNervous system disorders9/2728/276
ArthralgiaMusculoskeletal and connective tissue disorders8/2724/276
Pain in extremityMusculoskeletal and connective tissue disorders7/2725/276

Baseline characteristics

Intent-to-Treat Population (ITT) included all randomized participants with at least one dose of study drug. The ITT population was analyzed according to what the randomization schedule intended for the participants to take in each period.

Age, Continuous
Age, Continuous(years)Pregabalin/PlaceboPlacebo/PregablinTotal
Mean59.4 ± 9.858.4 ± 9.558.9 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin/PlaceboPlacebo/PregablinTotal
Female6572137
Male8975164
08

Study locations

61 sites
  • Dedicated Clinical Research
    Goodyear, Arizona 85395, United States
  • Clinical Research Consortium
    Phoenix, Arizona 85004, United States
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Advanced Podiatry
    Phoenix, Arizona 85032, United States
  • Precision Trials
    Phoenix, Arizona 85032, United States
  • The Office of Joshua D. Holland, M.D.
    Phoenix, Arizona 85053, United States
  • Genova Clinical Research
    Tucson, Arizona 85704, United States
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
  • Center for United Research, Inc.
    Lakewood, California 90712, United States
  • HealthCare Partners Medical Group
    Los Angeles, California 90015, United States
  • IDS Pharmacy
    Los Angeles, California 90033, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Coastal Connecticut Research, LLC
    New London, Connecticut 06320, United States
  • Neurological Group, PC
    New London, Connecticut 06320, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Meridien Research
    Bradenton, Florida 34208, United States
  • Meridien Research
    Brooksville, Florida 34601, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • AGA Clinical Trials
    Hialeah, Florida 33012, United States
  • Palm Beach Neurological Center,
    Palm Beach Gardens, Florida 33418, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Columbus Research Foundation
    Columbus, Georgia 31904, United States
  • Suburban Clinical Research
    Chicago, Illinois 60624, United States
  • Suburban Clinical Research
    Naperville, Illinois 60564, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • Arthritis and Diabetes Clinic, Inc.
    Monroe, Louisiana 71203, United States
  • Beacon Clinical Research, LLC
    Brockton, Massachusetts 02301, United States
  • Miray Medical Center
    Brockton, Massachusetts 02301, United States
  • Genesis Clinical Research, LLC
    Fall River, Massachusetts 02720, United States
  • Borgess Diabetes Center
    Kalamazoo, Michigan 49048, United States
  • Borgess Research Institute
    Kalamazoo, Michigan 49048, United States
  • Mercy Health Research
    Saint Louis, Missouri 63141, United States
  • Quality Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • Mirkil Medical Group
    Las Vegas, Nevada 89119, United States
  • V.Jerome Mirkil, MD
    Las Vegas, Nevada 89119, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • Davidson Medical Ministries
    Lexington, North Carolina 27292, United States
  • Radiant Research (admin office)
    Cincinnati, Ohio 45249, United States
  • Radiant Research
    Columbus, Ohio 43212, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • The Office of Veronique Sebastian, MD
    Oklahoma City, Oklahoma 73120, United States
  • Sunstone Medical Research, LLC
    Medford, Oregon 97504, United States
  • Blair Orthopedic Associates, Inc.
    Altoona, Pennsylvania 16602, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Neurology and Pain Clinic, LLC
    Orangeburg, South Carolina 29118, United States
  • New Phase Research and Development
    Knoxville, Tennessee 37919, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • Houston Neurocare
    Houston, Texas 77030, United States
  • Centex Research, Inc.
    Houston, Texas 77062, United States
  • UNARS, s.r.o.
    Pelhrimov, 39301, Czechia
  • Clintrial, s.r.o.
    Praha 10, 100 00, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czechia
  • Fondazione PTV Policlinico Tor Vergata di Roma
    Roma, 00133, Italy
  • Center for Lakemedelsstudier
    Malmo, 211 52, Sweden
  • Citydiabetes
    Stockholm, 111 57, Sweden
09

References and documents

Publications

  • Raskin P, Huffman C, Yurkewicz L, Pauer L, Scavone JM, Yang R, Parsons B. Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study. Clin J Pain. 2016 Mar;32(3):203-10. doi: 10.1097/AJP.0000000000000254. PubMed 25968451 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Nov 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2011
First posted
Oct 20, 2011
Start
Dec 2011
Primary completionActual
Nov 2013
CompletionActual
Dec 2013
Results first posted
Apr 23, 2015
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01455415
Responsible party
Sponsor
First posted
Oct 20, 2011
Start date
Dec 2011
Primary completion
Nov 2013
Completion
Dec 2013
Results posted
Apr 23, 2015
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion